NCT02625857View on ClinicalTrials.gov

Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 10, 2015

Primary Completion Date

July 3, 2018

Study Completion Date

July 3, 2018

Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
BIOLOGICAL

JNJ-64041809 (Cohort 1A and 1B)

JNJ-64041809 will be administered IV at a lower dose in Cohort 1A (1x10\^8 colony forming units \[CFU\]) and at a higher dose in Cohort 1B (1x10\^9 CFU).

BIOLOGICAL

JNJ-64041809 (Cohort 2A and 2B)

JNJ-64041809 will be administered intravenously (IV) once every 21 days at the recommended dose as determined in Cohort 1A or 1B.

Trial Locations (6)

Unknown

San Francisco

Baltimore

St Louis

Nashville

Houston

Madison

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02625857 - Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer | Biotech Hunter | Biotech Hunter